Cargando…

Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau

The relationship between the two most prominent neuropathological hallmarks of Alzheimer’s Disease (AD), extracellular amyloid-β (Aβ) deposits and intracellular accumulation of hyperphosphorylated tau in neurofibrillary tangles (NFT), remains at present not fully understood. A large body of evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zampar, Silvia, Wirths, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156793/ https://www.ncbi.nlm.nih.gov/pubmed/34069029 http://dx.doi.org/10.3390/ijms22105191

Ejemplares similares

Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer’s Disease
por: Gerberding, Anna-Lina, et al.
Publicado: (2019)

Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
por: Wirths, Oliver, et al.
Publicado: (2020)

A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model
por: Stazi, Martina, et al.
Publicado: (2023)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer’s disease
por: Marengo, Liana, et al.
Publicado: (2022)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease
por: Zampar, S., et al.
Publicado: (2020)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice
por: Stazi, Martina, et al.
Publicado: (2022)

N-truncated Aβ(4–x) peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
por: Wirths, Oliver, et al.
Publicado: (2017)

Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease
por: Wirths, Oliver, et al.
Publicado: (2010)

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau
por: Guo, Qinxi, et al.
Publicado: (2013)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Metabolic, Phenotypic, and Neuropathological Characterization of the Tg4-42 Mouse Model for Alzheimer’s Disease
por: Hinteregger, Barbara, et al.
Publicado: (2021)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Jia, Longfei, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation
por: Christensen, Ditte Z., et al.
Publicado: (2014)

Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ(42), Tau, and Phosphorylated Tau
por: Liu, Ziyi, et al.
Publicado: (2018)

Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Giesers, Naomi K., et al.
Publicado: (2020)

CSF T-Tau/Aβ(42) Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease
por: Bendlin, Barbara B., et al.
Publicado: (2012)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
por: Bouter, Yvonne, et al.
Publicado: (2013)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
por: Kwak, Sang Su, et al.
Publicado: (2020)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

The Validation of Multifactor Model of Plasma Aβ(42) and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease
por: Jiao, Fubin, et al.
Publicado: (2020)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Analysis of Motor Function in the Tg4-42 Mouse Model of Alzheimer’s Disease
por: Wagner, Jannek M., et al.
Publicado: (2019)

Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in Tau(−/−) mice
por: Vargas-Caballero, Mariana, et al.
Publicado: (2017)

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
por: Jäkel, Lieke, et al.
Publicado: (2019)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
por: Reinert, Jochim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_45g1th5jskgu5bmkitqqm5tntk